These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29532748)

  • 1. A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update.
    Guerrero A
    Curr Med Chem; 2018; 25(30):3597-3612. PubMed ID: 29532748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adenosine A2A receptor as a drug target for treatment of sepsis].
    Sivak KV; Vasin AV; Egorov VV; Tsevtkov VB; Kuzmich NN; Savina VA; Kiselev OI
    Mol Biol (Mosk); 2016; 50(2):231-45. PubMed ID: 27239843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role and Function of A
    Ravani A; Vincenzi F; Bortoluzzi A; Padovan M; Pasquini S; Gessi S; Merighi S; Borea PA; Govoni M; Varani K
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor.
    Preti D; Baraldi PG; Saponaro G; Romagnoli R; Aghazadeh Tabrizi M; Baraldi S; Cosconati S; Bruno A; Novellino E; Vincenzi F; Ravani A; Borea PA; Varani K
    J Med Chem; 2015 Apr; 58(7):3253-67. PubMed ID: 25780876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine A2A receptor as a drug discovery target.
    de Lera Ruiz M; Lim YH; Zheng J
    J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Therapeutic Applications of Adenosine A
    van Waarde A; Dierckx RAJO; Zhou X; Khanapur S; Tsukada H; Ishiwata K; Luurtsema G; de Vries EFJ; Elsinga PH
    Med Res Rev; 2018 Jan; 38(1):5-56. PubMed ID: 28128443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.
    Rodríguez D; Gao ZG; Moss SM; Jacobson KA; Carlsson J
    J Chem Inf Model; 2015 Mar; 55(3):550-63. PubMed ID: 25625646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Santinelli C; Spinaci A; Thomas A; Volpini R
    Mol Inform; 2016 Sep; 35(8-9):403-13. PubMed ID: 27546044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.
    Al-Attraqchi OHA; Attimarad M; Venugopala KN; Nair A; Al-Attraqchi NHA
    Curr Pharm Des; 2019; 25(25):2716-2740. PubMed ID: 31333093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the allosteric sites of the A
    Caliman AD; Miao Y; McCammon JA
    Chem Biol Drug Des; 2018 Jan; 91(1):5-16. PubMed ID: 28639411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis.
    Flögel U; Burghoff S; van Lent PL; Temme S; Galbarz L; Ding Z; El-Tayeb A; Huels S; Bönner F; Borg N; Jacoby C; Müller CE; van den Berg WB; Schrader J
    Sci Transl Med; 2012 Aug; 4(146):146ra108. PubMed ID: 22875828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor.
    Agrawal N; Chandrasekaran B; Al-Aboudi A
    Curr Pharm Des; 2019; 25(7):774-782. PubMed ID: 30848185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion of Wound Healing by an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen Activator.
    Montesinos MC; Desai-Merchant A; Cronstein BN
    Inflammation; 2015 Dec; 38(6):2036-41. PubMed ID: 25991438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A
    Fuentes E; Fuentes M; Caballero J; Palomo I; Hinz S; El-Tayeb A; Müller CE
    Platelets; 2018 May; 29(3):292-300. PubMed ID: 28504052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.
    Hothersall JD; Guo D; Sarda S; Sheppard RJ; Chen H; Keur W; Waring MJ; IJzerman AP; Hill SJ; Dale IL; Rawlins PB
    Mol Pharmacol; 2017 Jan; 91(1):25-38. PubMed ID: 27803241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of an agonist-bound human A2A adenosine receptor.
    Xu F; Wu H; Katritch V; Han GW; Jacobson KA; Gao ZG; Cherezov V; Stevens RC
    Science; 2011 Apr; 332(6027):322-7. PubMed ID: 21393508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a Na
    Noël F; do Monte FM
    J Pharmacol Toxicol Methods; 2017; 84():51-56. PubMed ID: 27810394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.
    Cristalli G; Lambertucci C; Marucci G; Volpini R; Dal Ben D
    Curr Pharm Des; 2008; 14(15):1525-52. PubMed ID: 18537675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death.
    Wagner CE; Pope NH; Charles EJ; Huerter ME; Sharma AK; Salmon MD; Carter BT; Stoler MH; Lau CL; Laubach VE; Kron IL
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):538-45. PubMed ID: 26323621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
    Cacciari B; Spalluto G; Federico S
    Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.